Was reports APC-300 kills human pancreatic cells

Current article ratings:
Patients / public:5 (1 votes)healthcare Prof:
Was Pharmaceuticals Corporation (OTCBB: ADMP) announced today that in addition to his work in prostate cancer, his drug APC-300 significantly inhibits the growth of pancreatic cells. Pancreatic cancer is still one of the deadliest forms of cancer. The mortality rate of pancreatic cancer striking compares its incidence. It is survival rate the worst forecasts with a total of less than 5%, and most patients die within the first two years. Recent results regarding the mechanism leads to the occurrence of pancreatic cancer suggest that more than 90% of pancreatic cancer was mutated RAS oncogene has. The mutation of RAS-induced was to the induction of several pathways inside the cell leads to the resistance of these cells to apoptosis (cell death) and the development of cancer combined.

In an attempt to understand induced APC-300 works, Dr. Hasan Mukhtar and his team at the University of Wisconsin, have human pancreatic adenocarcinoma cells and examined the effect of the APC-300 multiple RAS Signaling Pathways on tumor cell growth and influence. APC-300 treating cancer cells found the expression caused RAS to reduce significantly and to modulate the protein expression of different signaling molecules in cancer cell growth. APC-300 uses the cancer cells to multiple signalling pathways tumor cell death and the inhibition of growth of pancreatic cancer cells (life sciences, 2011 (88) pp. 285-293 and cancer Res. 2009, 69(3) 1156-65).

In addition, it was in a mouse model of pancreatic cancer, APC-300 shown that the growth of tumors (p reduce)
Dr. Dennis j. Carlo, PhD., President and CEO of was that "because of the known mechanisms of the effect of APC-300, and his ability, multiple signaling targets within the cancer cell be effect, this drug probably different tumors." "In fact we need to support date, the data, to be the case."

Source:
Was pharmaceuticals